Ranbaxy Launches AG Version Of Caduet As CEO Likens Lipitor Deal With Teva To An Insurance Policy
This article was originally published in PharmAsia News
Executive Summary
Both Ranbaxy and Mylan appear to have agreed to sell all doses of Caduet under separate authorized generic deals with Pfizer.